{"schema_version":"secwatch.filing_event.v1","accession":"0001082554-22-000021","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2022-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.919584+00:00","generated_at":"2026-06-24T04:49:38.099665+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"United Therapeutics Q2 2022 revenue up 5% to $466.9M; net income down 33%","bullets":["Total revenues $466.9M (+5% YoY); net income $116.0M ($2.41 diluted EPS) vs $172.6M ($3.65) in Q2 2021.","Tyvaso sales $201.0M (+31%) from PH-ILD label expansion; ~500 additional Tyvaso patients in Q2.","Share-based compensation $65.5M (+125%), driven by STAP expense from 31% stock price increase.","FDA approved Tyvaso DPI in May 2022 for PAH and PH-ILD; commercial shipments began in June.","CMS updated Tyvaso coverage for PH-ILD effective June 5, 2022, supporting further patient growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001082554-22-000021","json":"https://secwatch.observer/filing/0001082554-22-000021.json","markdown":"https://secwatch.observer/filing/0001082554-22-000021.md","text":"https://secwatch.observer/filing/0001082554-22-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000108255422000021/0001082554-22-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000108255422000021/uthr-20220803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:49:38.099665+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}